Hence, a significant proportion of older patients with TN and Her2-positive BC should receive neo-adjuvant chemotherapy (+/- Trastuzumab): cN1 or cN0 usN1 with positive axillary lymph node and cN0 pT2. This evidence concerns the gene ERBB2 and breast cancer.